Electronic "nose" (e-nose) technology that detects volatile organic compounds (VOCs) released by the body is being investigated as a noninvasive approach to cancer detection. Recent advances suggest these devices may eventually complement existing diagnostic methods by analyzing VOCs released through both breath and skin, according to an article published in the Journal of Medical Internet Research.
Cancer diagnosis currently relies on imaging, tissue biopsy, and laboratory testing, which can be invasive or time-consuming. E-noses are designed to detect patterns of VOCs produced during normal and abnormal metabolic processes, using sensor arrays combined with machine learning algorithms to distinguish cancer-associated chemical signatures from those seen in healthy individuals.
Most research has focused on VOCs in exhaled breath, where studies have reported potential applications for detecting lung, breast, gastric, and colorectal cancers. However, breath VOCs can be influenced by factors such as diet, smoking, medications, environmental exposures, and other medical conditions, making it difficult to identify cancer-specific patterns consistently.
Researchers are now investigating whether VOCs released through the skin could provide a more stable source of diagnostic biomarkers. Changes in cellular metabolism associated with cancer alter the chemical composition of VOCs emitted from the skin, creating patterns that may be detected by appropriately designed sensor systems.
The article highlights a pilot study published in the Journal of Analytical Chemistry that evaluated a quantum dot-based e-nose for bedside analysis of skin-emitted VOCs. The device used cadmium sulfide quantum dots to improve sensitivity for detecting selected chemical compounds associated with malignancy.
Researchers compared skin VOC profiles from patients with cancer and healthy volunteers. Healthy participants showed relatively consistent VOC patterns throughout the day, whereas patients with cancer demonstrated greater variability. Using these data, the investigators developed a statistical model that distinguished participants with and without cancer with reported sensitivity and accuracy of 100 percent in this pilot study. The system also showed potential for monitoring changes in disease status over time by detecting shifts in VOC profiles during treatment.
Although these findings are preliminary, they highlight a potential role for e-noses as complementary diagnostic tools. The technology could eventually support noninvasive cancer screening, help identify patients who require confirmatory testing, and provide an additional method for monitoring disease progression or treatment response. The authors emphasize that e-noses are not intended to replace established diagnostic approaches, including imaging, pathology, and biopsy, but could become an additional source of diagnostic information.
Further studies are planned to evaluate the technology in larger and more diverse patient populations, including outpatient settings, and to better define cancer-specific VOC signatures. Continued improvements in sensor technology, artificial intelligence, and biomarker analysis will also be needed before e-noses can be incorporated into routine clinical practice.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
